CBX6-CA9 Axis: An Epigenetic-Metabolic Vulnerability in Glioblastoma

Authors

• Keykavous Parang, Chapman UniversityFollow

Document Type

Response or Comment

Publication Date

3-25-2026

Abstract

Glioblastoma (GBM) remains one of the most therapeutically recalcitrant malignancies, with median survival rarely exceeding 15 months despite maximal therapy.¹ The hypoxic tumor microenvironment drives treatment resistance through epigenetic and metabolic adaptations.²

In this issue of Molecular Therapy Oncology, the study by Wang et al.³ demonstrates a novel regulatory axis between CBX6 (chromobox 6), a polycomb group protein, and CA9 (carbonic anhydrase 9), revealing how hypoxia-driven epigenetic reprogramming promotes tumor progression and identifying a mechanistically linked pathway for therapeutic intervention in GBM.

The study by Wang et al.3 advances our understanding of how the tumor microenvironment orchestrates epigenetic changes that promote malignant phenotypes. The demonstration that hypoxia dynamically regulates a polycomb group protein challenges traditional views of epigenetic regulation as static and highlights the importance of microenvironment-gene interactions in therapeutic design.

Comments

This article was originally published in Molecular Therapy Oncology, volume 34, issue 2, in 2026. https://doi.org/10.1016/j.omton.2026.201174

Recommended Citation

Parang K. CBX6-CA9 axis: An epigenetic-metabolic vulnerability in glioblastoma. Molecular Therapy Oncology. 2026;34(2):201174. https://doi.org/10.1016/j.omton.2026.201174

Copyright

The author

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.